221 related articles for article (PubMed ID: 35409391)
21. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
Gökbuget N; Zugmaier G; Dombret H; Stein A; Bonifacio M; Graux C; Faul C; Brüggemann M; Taylor K; Mergen N; Reichle A; Horst HA; Havelange V; Topp MS; Bargou RC
Leuk Lymphoma; 2020 Nov; 61(11):2665-2673. PubMed ID: 32619115
[TBL] [Abstract][Full Text] [Related]
22. Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease.
Mikhailova E; Semchenkova A; Illarionova O; Kashpor S; Brilliantova V; Zakharova E; Zerkalenkova E; Zangrando A; Bocharova N; Shelikhova L; Diakonova Y; Zhogov V; Khismatullina R; Molostova O; Buldini B; Raykina E; Larin S; Olshanskaya Y; Miakova N; Novichkova G; Maschan M; Popov AM
Br J Haematol; 2021 May; 193(3):602-612. PubMed ID: 33715150
[TBL] [Abstract][Full Text] [Related]
23. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.
van der Sluis IM; de Lorenzo P; Kotecha RS; Attarbaschi A; Escherich G; Nysom K; Stary J; Ferster A; Brethon B; Locatelli F; Schrappe M; Scholte-van Houtem PE; Valsecchi MG; Pieters R
N Engl J Med; 2023 Apr; 388(17):1572-1581. PubMed ID: 37099340
[TBL] [Abstract][Full Text] [Related]
24. Extramedullary relapse of
Aldoss I; Song JY
Blood; 2018 May; 131(22):2507. PubMed ID: 29853461
[No Abstract] [Full Text] [Related]
25. A Systematic Review of Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia: Engaging an Old Problem With New Solutions.
Halford Z; Coalter C; Gresham V; Brown T
Ann Pharmacother; 2021 Oct; 55(10):1236-1253. PubMed ID: 33435716
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
27. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
28. Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.
Wolach O; Stone RM
Clin Cancer Res; 2015 Oct; 21(19):4262-9. PubMed ID: 26283683
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of blinatumomab in Chinese adults with Ph-negative relapsed/refractory B-cell precursor acute lymphoblastic leukemia: A multicenter open-label single-arm China registrational study.
Zhou H; Yin Q; Jin J; Liu T; Cai Z; Jiang B; Li D; Sun Z; Li Y; He Y; Ma L; Gao S; Hu J; He A; Du X; Liu D; Zhang X; Ke X; Zhuang J; Han Y; Wang X; Chen Y; Gordon P; Yu D; Zugmaier G; Wang J
Hematology; 2022 Dec; 27(1):917-927. PubMed ID: 36000952
[TBL] [Abstract][Full Text] [Related]
30. ZNF384-related fusion genes define a subgroup of childhood B-cell precursor acute lymphoblastic leukemia with a characteristic immunotype.
Hirabayashi S; Ohki K; Nakabayashi K; Ichikawa H; Momozawa Y; Okamura K; Yaguchi A; Terada K; Saito Y; Yoshimi A; Ogata-Kawata H; Sakamoto H; Kato M; Fujimura J; Hino M; Kinoshita A; Kakuda H; Kurosawa H; Kato K; Kajiwara R; Moriwaki K; Morimoto T; Nakamura K; Noguchi Y; Osumi T; Sakashita K; Takita J; Yuza Y; Matsuda K; Yoshida T; Matsumoto K; Hata K; Kubo M; Matsubara Y; Fukushima T; Koh K; Manabe A; Ohara A; Kiyokawa N;
Haematologica; 2017 Jan; 102(1):118-129. PubMed ID: 27634205
[TBL] [Abstract][Full Text] [Related]
31. Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
Uphoff CC; MacLeod RA; Denkmann SA; Golub TR; Borkhardt A; Janssen JW; Drexler HG
Leukemia; 1997 Mar; 11(3):441-7. PubMed ID: 9067587
[TBL] [Abstract][Full Text] [Related]
32. Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Queudeville M; Stein AS; Locatelli F; Ebinger M; Handgretinger R; Gökbuget N; Gore L; Zeng Y; Gokani P; Zugmaier G; Kantarjian HM
Cancer; 2023 May; 129(9):1384-1393. PubMed ID: 36829303
[TBL] [Abstract][Full Text] [Related]
33. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.
Haddox CL; Mangaonkar AA; Chen D; Shi M; He R; Oliveira JL; Litzow MR; Al-Kali A; Hogan WJ; Elliott MA
Blood Cancer J; 2017 Sep; 7(9):e607. PubMed ID: 29016570
[No Abstract] [Full Text] [Related]
34. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
[TBL] [Abstract][Full Text] [Related]
35. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
[TBL] [Abstract][Full Text] [Related]
36. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
[TBL] [Abstract][Full Text] [Related]
37. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
[TBL] [Abstract][Full Text] [Related]
38. Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients.
Ampatzidou M; Kattamis A; Baka M; Paterakis G; Anastasiou T; Tzanoudaki M; Kaisari A; Avgerinou G; Doganis D; Papadakis V; Kitra V; Polychronopoulou S
Neoplasma; 2020 Nov; 67(6):1424-1430. PubMed ID: 32701357
[TBL] [Abstract][Full Text] [Related]
39. DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch.
Novakova M; Zaliova M; Fiser K; Vakrmanova B; Slamova L; Musilova A; Brüggemann M; Ritgen M; Fronkova E; Kalina T; Stary J; Winkowska L; Svec P; Kolenova A; Stuchly J; Zuna J; Trka J; Hrusak O; Mejstrikova E
Haematologica; 2021 Aug; 106(8):2066-2075. PubMed ID: 32646889
[TBL] [Abstract][Full Text] [Related]
40. TCF3 gene rearrangements in pediatric B-cell acute lymphoblastic leukemia-A single center experience.
Zerkalenkova E; Menchits Y; Borkovskaia A; Sokolova S; Soldatkina O; Mikhailova E; Popov A; Komkov A; Rumiantseva Y; Karachunskii A; Olshanskaya Y
Int J Lab Hematol; 2023 Aug; 45(4):533-540. PubMed ID: 37058324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
